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The  synthesis  of inﬂuenza  virus  mRNA  is  primed  by  capped  (m7GpppNm-)  short  RNAs  that  are  cleaved
from  RNA  polymerase  II transcripts  by  a virally  encoded  endonuclease.  This  cap-dependent  endonuclease
activity  called  “cap-snatching”  may  provide  a unique  target  for novel  anti-viral  agents.  To  screen  candi-
date  inhibitors,  it is  essential  to  establish  a method  for producing  efﬁciently  a capped  RNA  substrate  and
a convenient  assay  for the  cap-snatching  activity.  A 3′-biotinylated  short  RNA  was  prepared  by in  vitro
transcription,  puriﬁed  by  C18 reverse-phase  column  chromatography,  and  subjected  to  a capping  reactionRNA capping
nﬂuenza virus
ap-snatching
ntiviral agent
involving  three  recombinant  capping  enzymes.  This  capped  RNA  was shown  to  be an  efﬁcient  substrate
for  the  cap-snatching  assay.  Cap-snatching  activity  was then  measured  with  the  novel  pull-down  assay
developed  in  this  study,  which  is based  on  the streptavidin–biotin  interaction.  A  known  inhibitor  for
the  cap-snatching  reaction  was  evaluated  by  the  pull-down  assay,  demonstrating  the  efﬁcacy  of  the
established  screening  system.
© 2014  The  Authors.  Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
Inﬂuenza virus causes acute respiratory infections in humans
hat sometimes progress to severe pulmonary diseases, resulting
n considerable mortality among elderly and other high-risk indi-
iduals. Because the currently available vaccines do not protect
ompletely against inﬂuenza virus infections, there is an urgent
eed for the development of anti-inﬂuenza therapeutic agents.
here are currently only two kinds of licensed drugs for inﬂuenza
irus, neuraminidase inhibitors (oseltamivir and zanamivir) and
2 channel blockers (amantadine and rimantadine) (De Clercq,
006; Salomon and Webster, 2009; Das et al., 2010; Das, 2012).
owever, many inﬂuenza type A virus strains have become resis-
ant to these M2 channel blockers and/or neuraminidase inhibitors
Hayden et al., 1989; Bright et al., 2005; Le et al., 2005).
The inﬂuenza virus genome consists of eight segmented RNA
olecules with negative polarity. The single-stranded genomic
NAs are transcribed and replicated by a virally encoded RNA-
ependent RNA polymerase, which is composed of three subunits,
B1, PB2, and PA (Horisberger, 1980). The translation of the viral
∗ Corresponding author. Tel.: +81 3 5791 6246.
E-mail address: shibagakiy@pharm.kitasato-u.ac.jp (Y. Shibagaki).
ttp://dx.doi.org/10.1016/j.jviromet.2014.02.005
166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
mRNAs by host ribosomes requires that the mRNAs are capped,
to allow their recognition and binding. However, inﬂuenza virus
RNA polymerase does not carry the enzymatic activities required
to add a 5′ cap to its own  mRNAs, so the necessary cap structure
is “snatched” from host pre-mRNA transcripts (Bouloy et al., 1978,
1980; Plotch et al., 1981; Ulmanen et al., 1981). Inﬂuenza virus RNA
polymerase binds to the host pre-mRNA transcripts through their
cap structures and cleaves them to generate capped RNAs of 11–13
nucleotides, which are used as the primers for viral transcription
(Bouloy et al., 1978, 1980; Plotch et al., 1981; Ulmanen et al., 1981).
This cap-snatching reaction may  be used as a novel target for the
development of anti-inﬂuenza-virus agents because this reaction is
a unique and essential mechanism for inﬂuenza virus transcription.
In eukaryotes, most cellular and viral mRNAs have 5′ cap struc-
tures consisting of 7-methylguanosine linked to the initiating
nucleotide of the transcripts via an inverted 5′–5′ triphosphate
bridge (m7G(5′)ppp(5′)N; Cap 0) (Banerjee, 1980; Mizumoto and
Kaziro, 1987; Furuichi and Shatkin, 2000; Decroly et al., 2011).
The Cap 0 structure is essential for the growth of Saccharomyces
cerevisiae (Shibagaki et al., 1992; Mao  et al., 1995) and the sur-
vival of mammalian cells (Yue et al., 1997). The Cap 0 structure
is further methylated at 2′-O-ribose, either at the ﬁrst nucleotide
(m7G(5′)ppp(5′)Nm; Cap 1) or at the ﬁrst and second nucleotides
(m7G(5′)ppp(5′)NmNm; Cap 2) in higher eukaryotes by nucleoside
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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′-O-methyltransferases (Banerjee, 1980; Furuichi and Shatkin,
000).
The Cap 0 structure is formed by three enzymatic reactions:
1) RNA 5′-triphosphatase (TPase) hydrolyzes the 5′ triphosphate
nd of the pre-mRNA to a diphosphate; (2) mRNA guanylyltrans-
erase (GTase) adds a guanosine monophosphate (GMP) residue to
he diphosphate end of the RNA; and (3) m7G-methyltransferase
m7G-MTase) methylates GpppN- to form the Cap 0 structure
Banerjee, 1980; Mizumoto and Kaziro, 1987; Furuichi and Shatkin,
000; Decroly et al., 2011). These three enzymes are present in
he virion of vaccinia virus, reovirus, and cytoplasmic polyhe-
rosis virus (Shuman et al., 1980). Vaccinia virus also uses cap1
RNA nucleoside 2′-O-methyltransferase (cap1 MTase) to con-
ert Cap 0 to the Cap 1 structure (Schnierle et al., 1992). Many
ellular capping enzymes and m7G-MTase have also been iso-
ated from humans (hCap1, hMet1) (Tsukamoto et al., 1998a,b;
amada-Okabe et al., 1998), mice (Mce1) (McCracken et al., 1997),
aenorhabditis elegans (CEL-1) (Takagi et al., 1997), S. cerevisiae
CEG1, CET1, ABD1) (Shibagaki et al., 1992; Mao  et al., 1995;
sukamoto et al., 1997), and Schizosaccharomyces pombe (Pce1,
ct1) (Shuman et al., 1994; Pei et al., 2001). Recently, human cap1
RNA (nucleoside-2′-O-)-methyltransferase (hMTr1) (Belanger
t al., 2010) and cap2 mRNA (nucleoside-2′-O-)-methyltransferase
hMTr2) (Werner et al., 2011) were identiﬁed.
The inﬂuenza type A virus RNA polymerase cleaves preferen-
ially RNA with 5′ Cap 1 over that with Cap 0, but not RNA with an
nmethylated core cap (Wakai et al., 2011). The RNA polymerase
rom the type B virus shows similar substrate speciﬁcity, with the
xception that the type B RNA polymerase also cleaves RNA with an
nmethylated core cap (Wakai et al., 2011). Consistent with this,
he in vitro transcription activity of inﬂuenza virus is stimulated
ore by mRNA methylated at 2′-O-ribose residues than by mRNA
acking 2′-O-ribose methylation (Bouloy et al., 1980). Therefore, it
s necessary to establish a procedure to prepare an RNA substrate
ith the Cap 1 structure for the development of a screening system
or anti-cap-snatching agents.
To date, only a few studies have described an inhibitor of cap-
natching activity (Tomassini et al., 1994, 1996; Hsu et al., 2012).
n these studies, the mRNA of alfalfa mosaic virus RNA 4 was
rst decapped in vitro, and then capped using enzymes puriﬁed
rom vaccinia virus to prepare the substrate. However, this com-
licated substrate preparation procedure and the heterogeneity of
he natural RNA might hinder the efﬁcient screening of candidate
ompounds.
During biochemical and molecular biological studies of the cap-
ing enzymes, we puriﬁed these enzymes from various sources,
ncluding mammalian cells, brine shrimp, and yeast, analyzed the
iochemical mechanism of cap formation (reviewed in Mizumoto
nd Kaziro, 1987), and cloned the genes of these enzymes from
umans (Tsukamoto et al., 1998a,b) and yeast (Shibagaki et al.,
992; Tsukamoto et al., 1997). Based on these studies, a novel
ethod to produce a short Cap 1-RNA with 3′-biotinylation
nd a convenient streptavidin–biotin-based pull-down assay for
creening anti-inﬂuenza-virus compounds that target the viral cap-
natching activity have been developed in this study. An RNA
ligonucleotide with biotinylated uridine monophosphate (UMP)
t its 3′ end was synthesized by in vitro transcription using T7
NA polymerase, and was separated from any prematurely ter-
inated products by C18 reverse-phase column chromatography.
he Cap 1 structure was added to the full-length RNA with an
fﬁciency of over 95% using three recombinant capping enzymes.
his capped RNA was shown to be an efﬁcient substrate for the
nﬂuenza virus cap-snatching activity. A known inhibitor of the
ap-snatching reaction (Tomassini et al., 1994) could be evaluated
ith this system, demonstrating the efﬁcacy of the system for the
creening of antiviral compounds.ical Methods 202 (2014) 8–14 9
2. Materials and methods
2.1. Inﬂuenza virus
Inﬂuenza virus A/PR/8/34 (H1N1) was  kindly supplied by Dr. M.
Yamasaki (Institute of Microbial Chemistry, Japan).
2.2. Recombinant enzymes
DNA fragments encoding the N-terminal domain of the vac-
cinia virus D1R subunit (D1N, amino acid residues 1–536, RNA
5′-triphosphatase and mRNA guanylyltransferase; GenBank
accession: AGB75827.1), S. cerevisiae ABD1 ([guanine-N-]-
methyltransferase; GenBank accession: AAA34383.1), and
vaccinia virus VP39 ([nucleoside-2′-O-]-methyltransferase;
GenBank accession: AAB19921.1) were PCR ampliﬁed from
the full-length vaccinia virus D1R subunit DNA  (a kind gift
from Dr. S. Shuman [Memorial Sloan-Kettering Cancer Center,
USA] (Shuman, 1990)), genomic DNA from S. cerevisiae NN1
(Yamagishi et al., 1995), and the genomic DNA of vaccinia
virus WTF7-3 (kindly provided by Dr. T. Nakayama [Kitasato
Institute for Life Sciences, Japan]), respectively, using following
primers: D1N, D1Nf (5′-GGCATATGGATGCCAACGTAGTATC-
3′) and D1Nr (5′-GGAAGCTTAATCCGATAGTTTATCCTC-3′);
ABD1, yABDf (5′-CCAGTGCATATGTCAACCAAACCAG-3′) and
yABDr (5′-CCCGGATCCTCAGTTGGGCTTTACGC-3′); VP39, VP39f
(5′-GGCATATGGATGTTGTGTCGTTAGATAAACC-3′) and VP39r (5′-
CCGGATCCTTATTTATTACCGCGTACGGATCTC-3′). The ampliﬁed
fragments were digested with appropriate restriction enzymes
(D1N, Nde I and Hind III; ABD1, Nde I and BamH I; VP39,
Nde I and BamH I) and inserted into correspondingly digested
pT7-7(His) (Shibagaki et al., 1997). The resultant plasmids,
pHis(T)–D1N(1–536), pHis(T)–ABD1, and pHis(T)–VP39, respec-
tively, were introduced into Escherichia coli BL21(DE3)pLysS
(Studier et al., 1990). The transformed cells were grown in LB
medium containing 50 g/ml ampicillin at 25 ◦C. When OD600
reached 1.0, protein expression was induced with isopropylth-
iogalactoside (0.5 mM)  and the cells were harvested after 5 h in
culture at 25 ◦C.
The E. coli pellet (3 g) was  suspended in 40 ml  of lysis buffer
(20 mM  Tris–HCl [pH 8.0], 100 mM NaCl, 5 mM 2-mercaptoethanol,
0.2 mM EDTA, 10% glycerol, 1 mM phenylmethanesulfonyl ﬂuoride)
and 0.5% Triton X-100. After lysis by sonication and clariﬁca-
tion by centrifugation, the supernatant was  applied to Ni+-NTA
agarose (Qiagen, Germany). The column was eluted with a gradi-
ent of imidazole (20–300 mM)  in Buffer A (20 mM Tris–HCl [pH
8.0], 100 mM NaCl, 5 mM 2-mercaptoethanol, and 10% glycerol).
D1N, ABD1, and VP39 were eluted at around 100 mM,  100–200 mM,
and 100–150 mM imidazole, respectively. The fractions containing
the recombinant enzymes were pooled, dialyzed against Buffer B
(20 mM  Tris–HCl [pH 7.0], 20 mM NaCl, 1 mM EDTA, 1 mM DTT,
10% glycerol), and applied to a High-Trap SP Sepharose FPLC
column (∅ 0.4 cm × 2 cm;  Amersham Biosciences, Sweden). The
column was eluted with a linear gradient of NaCl (0.05–1.0 M)
in Buffer B. D1N, ABD1, and VP39 were eluted at 200–300 mM,
300–400 mM,  and 400–500 mM NaCl, respectively. The fractions
containing the recombinant enzymes were pooled, dialyzed against
Buffer C (20 mM HEPES-Na [pH 7.9], 1 mM EDTA, 100 mM NaCl,
1 mM DTT, and 50% glycerol), and stored in aliquots at −80 ◦C until
use.
2.3. Synthesis of biotinylated Cap 1-RNA (m7GpppGm-RNA)A triphosphate-ended RNA (32 nucleotides: 5′-GAACAACAA-
AAAAAACAACCAACAACCAAAU-biotin-3′), designated “GACU32-
biot”, was synthesized using T7 RNA polymerase (Ambion, USA)
1 irological Methods 202 (2014) 8–14
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Fig. 1. A schematic illustration of synthesis of Cap 1-RNA with 3′-biotinylation. A
32-base RNA with 3′-biotinylation (GACU32-biot) was synthesized by in vitro tran-
scription from a synthetic DNA template, using T7 RNA polymerase, [-32P]GTP
(400 cpm/pmol), ATP, CTP, and biotin-16-UTP. After puriﬁcation by reverse-phase
column chromatography, the radioactive Cap 1 structure (2 × 105 cpm/pmol) was
added to GACU32-biot in sequential reactions with vaccinia virus D1N, S. cerevisiae0 Y. Shibagaki et al. / Journal of V
ith synthetic DNA as the template (template strand, 5′-ATTT-
GTTGTTGGTTGTTTTTTTTGTTCTTCTATAGTGAGTCGTATTAAGCTT-
′; coding strand, 5′-AAGCTTAATACGACTCACTATAGAA-3′;
nderlined sequences are complementary). For in vitro tran-
cription, 100 l of a solution containing 40 mM Tris–HCl (pH
.0), 12 mM  MgCl2, 1 mM spermidine, 0.05% Triton X-100, 5 mM
TT, 2 mM ATP, 2 mM CTP, 0.25 mM [-32P]GTP (400 cpm/pmol;
nstitute of Isotopes, Hungary), 0.5 mM biotin-16-UTP (Epicentre,
SA), 20 pmol of template DNA, and 500 U of T7 RNA polymerase
as incubated at 37 ◦C for 3 h. After the reaction, 1 ml  of 50 mM
mmonium bicarbonate (pH 8.0) was added and the sample
as loaded onto a C18 reverse-phase cartridge column (InertSep
limJ C18, 500 mg;  GL Science, Japan). The column was washed
wice with 5 ml  of 50 mM ammonium bicarbonate (pH 8.0) and
hree times with 1 ml  of 50 mM ammonium bicarbonate (pH 8.0)
ontaining 2% CH3CN. GACU32-biot was eluted with a stepwise
ncrease in the CH3CN concentration from 4% to 10% in 50 mM
mmonium bicarbonate (pH 8.0). Each fraction was analyzed by
 M urea/18% polyacrylamide gel electrophoresis, and the fractions
ontaining GACU32-biot but no prematurely terminated products
ere pooled, lyophilized, and subjected to the next capping
eaction.
GACU32-biot was capped as described previously with recom-
inant enzymes, as follows. GACU32-biot (50 pmol) was  incubated
ith vaccinia virus D1N (0.5 g), yeast ABD1 (1.5 g), vaccinia
irus VP39 (1.8 g), and 10 M [-32P]GTP (2 × 105 cpm/pmol)
t 37 ◦C for 2 h in a reaction mixture (100 l) containing 40 mM
ris–HCl (pH 7.9), 1.5 mM MgCl2, 40 mM NaCl, 5 mM  DTT, 0.1 mM
-adenosyl-l-methionine, 0.2 mg/ml  bovine serum albumin, and
0 U of RNase inhibitor (Takara, Japan). After the reaction, the
apped RNA was extracted with phenol–chloroform, precipitated
ith ethanol, and dissolved in 2% CH3CN.
To conﬁrm the cap structure on GACU32-biot (5′-terminally
abeled with [-32P]GTP (400 cpm/pmol)), nonradioactive GTP was
sed in the capping reaction, and the cap structure was liberated
y digestion with nuclease P1 (Wako Pure Chemical Industries,
apan) (Belanger et al., 2010). The product was analyzed by
olyethyleneimine–cellulose thin-layer chromatography (PEI-CEL
V254; Macherey-Nagel, Germany) with 0.3 M (NH4)2SO4 as a sol-
ent and visualized by FLA-7000 ﬂuorescent image analyzer (Fuji
ilm, Japan).
.4. Assays for inﬂuenza virus endonuclease (cap-snatching)
ctivity
Cap-snatching activity was measured in a reaction mixture
25 l) containing 50 mM Tris–HCl (pH 7.9), 0.1 M ammonium
cetate, 1.5 mM MgCl2, 2.5 mM  DTT, 0.1% Nonidet P-40, 4 U of
Nasin, 30–50 fmol [32P]Cap 1-GACU32-biot (2 × 105 cpm/pmol),
nd the indicated amount of inﬂuenza virus A virions. The sam-
les were incubated at 37 ◦C for 1 h. After the reaction, halves
f the products were extracted with phenol–chloroform, precip-
tated with ethanol, and analyzed with 18% polyacrylamide gel
lectrophoresis in the presence of 7 M urea (Klumpp et al., 2001;
akai et al., 2011). The RNAs were visualized by autoradiography
r analyzed with an FLA-7000 ﬂuorescent image analyzer. Endonu-
lease activity is expressed as a ratio of the cleaved RNA to the total
apped RNA.
The remaining halves of the samples were mixed with 200 l of
top solution (20 mM Tris–HCl [pH 8.0], 5 mM EDTA, and 150 mM
aCl) containing 30 g of Dynabeads® M-280 Streptavidin (Dynal,
orway) for 10 min  at room temperature. The mixtures were
oured onto 200 l pipette tips the ends of which were ﬁlled with
 small piece of GF/C glass ﬁlter (Whatman, UK). Each tip was
laced in a 2 ml  tube with an adapter for a centrifuge (Glygen, USA),
nd centrifuged at 2000 × g for 2 min. The Dynabead-bound andABD1, and vaccinia virus VP39. The small and large asterisks indicate the radioac-
tive  phosphates (400 cpm/pmol and 2 × 105 cpm/pmol, respectively) in the Cap 1
structure.
unbound fractions were quantiﬁed separately by measuring the
Cerenkov radiation, and the ratio of cleaved RNA to total capped
RNA was calculated.
3. Results
3.1. Synthesis and puriﬁcation of a short RNA with
3′-biotinylation for the cap-snatching assay
A short biotinylated Cap 1-RNA (m7G-pppGm-RNA) was  syn-
thesized to screen candidate agents that inhibit inﬂuenza virus
cap-snatching activity, which is shown schematically in Fig. 1. An
RNA (GACU32-biot) was prepared by in vitro transcription using T7
RNA polymerase and biotin-16-UTP, and the full-length product
was separated from the prematurely terminated products by C18
reverse-phase cartridge column chromatography. The Cap 1 struc-
ture was  then added to GACU32-biot using recombinant enzymes,
which were expressed in and puriﬁed from E. coli as His-tagged
proteins, as described below.
A DNA template for T7 RNA polymerase transcription was
designed to contain a short stretch of “A” residues 11–13
nucleotides from the transcription start site, because the inﬂuenza
virus polymerase prefers “A” residues around the cleavage site
of the cap-snatching reaction (Wakai et al., 2011) (Fig. 1). As a
general property, T7 RNA polymerase synthesizes 10- to 20-fold
more prematurely terminated products (2–3 nucleotides long)
than full-length RNA (Milligan and Uhlenbeck, 1989). Therefore,
a C18 reverse-phase cartridge column was used to remove the
prematurely terminated RNAs, which strongly inhibit the capping
reaction (see Section 4).
Fig. 2 shows a typical result of RNA puriﬁcation. [-32P]GTP
(400 cpm/pmol) was  included in the transcription reaction to mon-
itor the distribution of RNAs during subsequent chromatography.
As described above, the products of in vitro transcription contained
masses of prematurely terminated RNAs besides the full-length
GACU32-biot. Under the electrophoretic conditions (7 M urea/18%
PAGE), free [-32P]GTP moved faster than bromophenol blue (BPB),
and the position of BPB was slightly lower than that of prematurely
terminated RNAs (Fig. 2). GACU32-biot bound strongly to the col-
umn  in a solution containing 50 mM ammonium bicarbonate (pH
8.0), whereas the prematurely terminated RNAs bound negligibly to
Y. Shibagaki et al. / Journal of Virological Methods 202 (2014) 8–14 11
Fig. 2. Puriﬁcation of GACU32-biot. The product of in vitro transcription (input) was
puriﬁed with C18 reverse-phase cartridge column chromatography. After the col-
umn  was washed with 50 mM ammonium bicarbonate (pH 8.0), the column was
developed with a stepwise increase in the CH3CN concentration. Each fraction was
analyzed by 18% polyacrylamide gel electrophoresis in the presence of 7 M urea, and
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Fig. 3. Puriﬁcation of the recombinant enzymes from E. coli extracts. The puriﬁ-
cation of vaccinia virus D1N (residues 1–536), S. cerevisiae ABD1, and vaccinia
virus VP39 is shown. Aliquots of the E. coli extracts were puriﬁed with sequen-
tial  Ni+-agarose (1 g, Ni+) and SP Sepharose (1 g, SP) and then subjected to
10% SDS–polyacrylamide gel electrophoresis. The proteins were visualized with
Coomassie Brilliant Blue staining. (A) Puriﬁcation of the N-terminal region of the
vaccinia virus D1R subunit. The positions of the molecular weight markers are
shown on the left (myosin (230 kDa), -galactosidase (136 kDa), phosphorylase b
(95  kDa), bovine serum albumin (70 kDa), ovalbumin (44 kDa), and carbonic anhy-
Fig. 4. Synthesis and analysis of Cap 1-GACU32-biot. (A) Three sequential reac-
tions were used to convert the triphosphate end of GACU32-biot to produce Cap
1-GACU32-biot. Each product was digested with nuclease P1 (which hydrolyzes
all phosphodiester bonds, except those in Cap, represented by “slash” sym-
bols), and the resulting products were analyzed by thin-layer chromatography
on  polyethyleneimine–cellulose with 0.3 M ammonium sulfate as the solvent. Thehe  RNAs were visualized by an image analyzer input, 1/1000 of the applied mate-
ial; unbound, 1/1000 of the unbound fraction; 2%, 4% and 5%, 1/100 of the eluates;
%,  8% and 10%, 1/20 of the eluates.
t. After washing the column with 50 mM ammonium bicarbonate,
he column was developed by a stepwise increase in acetonitrile
CH3CN) concentration from 2 to 10%. The fractions containing
ACU32-biot but not premature RNAs were lyophilized, and then
ubjected to the capping reaction.
.2. Synthesis of Cap 1-RNA (m7GpppGm-RNA) for the
ap-snatching assay
Because the inﬂuenza type A virus cap-dependent endonu-
lease prefers RNA containing Cap 1 (m7GpppNm-RNA) as a
ubstrate over RNA containing Cap 0 (m7GpppN-RNA), it was
ecessary to convert the puriﬁed RNA into Cap 1-RNA. Four
eactions are required for the synthesis of the Cap 1 structure
Fig. 1). As described in Section 2, the N-terminal region of the
accinia virus D1R subunit (D1N, amino acid residues 1–536,
NA 5′-triphosphatase and mRNA guanylyltransferase), S. cere-
isiae ABD1 ([guanine-N-]-methyltransferase), and vaccinia virus
P39 ([nucleoside-2′-O-]-methyltransferase) as His-tagged pro-
eins were expressed in E. coli and puriﬁed them by sequential
olumn chromatography on Ni-NTA agarose and SP Sepharose. The
uriﬁed enzymes were analyzed by 10% SDS–polyacrylamide gel
lectrophoresis and the proteins were visualized by Coomassie Bril-
iant Blue staining (Fig. 3). All three enzymes were puriﬁed to near
omogeneity and were free of detectable nuclease and phosphatase
ctivities (data not shown).
GACU32-biot was incubated with the indicated enzymes (D1N,
BD1, and VP39) for 60 min  at 37 ◦C (Fig. 4), as described in
ection 2, except that nonradioactive GTP was  used to moni-
or the cap synthesis. Each product was digested with nuclease
1, which hydrolyzes all phosphodiester bonds of single-stranded
NA (generating 3′-hydroxyl ends), except those in the cap
tructure (Fig. 4A). The resulting products were analyzed by thin-
ayer chromatography on polyethyleneimine–cellulose with 0.3 M
mmonium sulfate as the solvent (Fig. 4B). As expected, the pppG
erminus of GACU32-biot (lane 1) was converted to GpppG bydrase (32 kDa)), (B) S. cerevisiae ABD1 and (C) vaccinia virus VP39.
D1N (lane 2), then to m7GpppG by ABD1 (lane 3), and ﬁnally to
m7GpppGm by VP39 (lane 4), with nearly a complete efﬁciency. To
synthesize the substrate RNA for the cap-snatching assay, highly
radioactive [-32P]GTP (2 × 105 cpm/pmol, speciﬁc activity 500-
fold higher than that used to label GACU32-biot) was  used to label
the Cap 1 structure.asterisks represent the radioactive phosphates. In this experiment, nonradioactive
GTP was  used in the capping reaction. SAM denotes S-adenosyl-l-methionine and
(B) a representative result of the capping reaction with the indicated recombinant
enzymes. After digestion with nuclease P1, the samples were analyzed by thin-layer
chromatography, followed by autoradiography.
12 Y. Shibagaki et al. / Journal of Virological Methods 202 (2014) 8–14
Fig. 5. Assays for cap-snatching activity. [32P]Cap 1-GACU32-biot (50 fmol) was
incubated with increasing amounts (0.25–1.25 g) of inﬂuenza virus A virions. The
products of the reaction were divided into two  equal samples. One was  analyzed
on 18% polyacrylamide gel with 7 M urea, followed by autoradiography (A). The
endonuclease activity is expressed as the ratio of the amount of cleaved RNA to the
amount of total capped RNA. The second sample was subjected to the pull-down
assay, as described in Section 2. The unbound and bound fractions were quanti-
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Fig. 6. Inhibition of cap-snatching activity by 2-hydoroxy-4-oxo-4-phenyl-2-
butenoic acid. The cap-snatching reaction was  performed as in Fig. 5 with inﬂuenza A
virions (1 g) in the presence of the indicated concentrations of 2-hydroxy-4-oxo-4-ed separately by measuring the Cerenkov radiation. The ratios of cleaved RNA
etermined by gel electrophoresis (open circles) and by the pull-down assay (closed
ircles) are shown. Typical results of three independent experiments are shown.
.3. Cap-snatching assay
[32P]Cap 1-GACU32-biot was tested to determine whether it is a
ubstrate of the inﬂuenza virus cap-snatching activity (Fig. 5). Two
ethods were employed to measure cap-snatching activity: one
as 18% polyacrylamide gel electrophoresis in the presence of 7 M
rea; and the other was a novel pull-down method established in
his study, based on the streptavidin–biotin interaction. [32P]Cap
-RNA was incubated with increasing amounts of the inﬂuenza
ype A virion in the presence of 0.1% Nonidet P-40. After the reac-
ion, the reaction products were divided into two equal samples.
ne sample was analyzed by 18% denaturing polyacrylamide gel
lectrophoresis and autoradiography, clearly demonstrating that
32P]Cap 1-RNA was a good substrate for the reaction (Fig. 5A).
n the pull-down assay, the radioactivity in the Cap 1 struc-
ure of GACU32-biot is trapped by streptavidin-conjugated beads
efore the cap-snatching reaction, whereas the radioactivity in the
leaved RNA after the cap-snatching reaction is recovered in the
upernatant fraction. The second sample (the other half of the
ap-snatching reaction products) was mixed with paramagnetic
treptavidin-conjugated Dynabeads®, and the unbound and bound
ractions were separated and quantiﬁed as described in Section 2.
he cap-snatching activity measured with the pull-down assay cor-
elated well with that evaluated by gel electrophoresis (Fig. 5B),
emonstrating the reliability of the novel pull-down assay.
A known inhibitor of the cap-snatching reaction, 2-hydroxy-4-
xo-4-phenyl-2-butenoic acid (compound 5 of (Tomassini et al.,
994), was tested with the pull-down method. This compound
howed an IC50 value of 65 M,  which is close to the value described
n the literature (Tomassini et al., 1994), conﬁrming the efﬁcacy of
he pull-down assay system (Fig. 6).
. Discussion
In this study, an efﬁcient screening system for inhibitors of
nﬂuenza virus cap-snatching activity was established. A short RNA
ith 3′-biotinylation was synthesized using T7 RNA polymerase,
uriﬁed by C18 reverse-phase column chromatography, and capped
ith three recombinant enzymes. This Cap 1-RNA was shown to be
 good substrate for the inﬂuenza virus cap-snatching activity. A
onvenient streptavidin–biotin-based pull-down assay to measure
his cap-snatching activity was also developed.
To screen a large number of compounds, it is essential to synthe-
ize the substrate RNA with the Cap 1 structure in large quantitiesphenyl-2-butenoic acid. The cleavage of [32P]Cap 1-GACU32-biot was measured with
the  pull-down assay, and the data are expressed as percentage inhibition compared
with the sample processed without the drug (60% cleavage).
and in a homogeneous state with respect to its cap structure and the
length of the RNA. In previous studies, the Cap 1-RNA substrate was
prepared by capping previously decapped alfalfa mosaic virus RNA
with [-32P]GTP (Tomassini et al., 1994, 1996; Hsu et al., 2012).
However, it is difﬁcult to prepare natural RNAs in large quanti-
ties. Therefore, this procedure may not be suitable for large-scale
screening.
The substrate RNA was  synthesized by in vitro transcription
with T7 RNA polymerase. However, as a general property, T7 RNA
polymerase synthesizes 10- to 20-fold more prematurely termi-
nated products (2–3 nucleotides long) than full-length RNAs (Fig. 2)
(Milligan and Uhlenbeck, 1989), and these may  competitively
inhibit the capping of the full-length RNA. Indeed, when the in vitro-
transcribed RNA was subjected to the capping reaction without
puriﬁcation, more than half the cap structures were Cap 0 (data
not shown). Polyacrylamide gel electrophoresis under denaturing
conditions has been used to purify the full-length RNA (Milligan and
Uhlenbeck, 1989; Tomassini et al., 1994, 1996; Hsu et al., 2012), but
the yield from the polyacrylamide gel was  generally low. Therefore,
the full-length RNA (GACU32-biot) was  puriﬁed by C18 reverse-
phase cartridge column chromatography. By increasing the CH3CN
concentration in a stepwise manner, GACU32-biot was  separated
completely from the prematurely terminated products (Fig. 2).
The full-length RNA (GACU32-biot) was  subjected to the cap-
ping reaction using recombinant enzymes. cDNA expression
plasmids for vaccinia virus DIR, as RNA 5′-triphosphatase and
mRNA guanylyltransferase, S. cerevisiae ABD1 as (guanine-N-)-
methyltransferase, and vaccinia virus VP39 as (nucleoside-2′-
O-)-methyltransferase were constructed. These proteins were
expressed in E. coli and puriﬁed to near homogeneity without
detectable RNase activity (data not shown). The concentrations of
the capping enzymes were set so that each step proceeded nearly
stoichiometrically (Fig. 4). Under the optimal conditions, 1 nmol of
Cap 1-GACU32-biot was  easily synthesized, which was enough for
10,000 assays.
When the RNA substrate to be capped contained a lot of pre-
mature products, as described above, or when the capping reaction
was performed using insufﬁcient enzymes, intermediate products
containing Cap 0 or the core Cap were present (data not shown).
Therefore, it is obviously necessary to analyze the cap structure by
nuclease Pl digestion, followed by thin-layer chromatography, as
we did in this study, to guarantee the homogeneity of the RNA sub-
strate. However, in most preceding studies, the homogeneity of the
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ap structure was not assessed. Enzymological studies are neces-
ary to develop a good inhibitor of cap-snatching. For such studies,
he homogeneity of the substrate may  be a critical requirement.
Successful GACU32-biot puriﬁcation and subsequent capping
f the puriﬁed RNA with a high yield allowed us to establish a
treptavidin–biotin-based pull-down assay for the cap-snatching
ctivity. In this assay, the radioactivity in the cap structure becomes
etached from the streptavidin beads upon cap-snatching because
he substrate RNA binds to the streptavidin beads through the
′-terminal biotinylated UMP. Prematurely terminated RNAs, if
resent in the substrate, may  cause background noise in the pull-
own assay because these molecules do not bind to the streptavidin
eads, regardless of the viral cap-snatching activity. Because the
nﬂuenza type A virus prefers RNAs with the Cap 1 structure over
hose with the Cap 0 structure, it is also critical to add the Cap 1
tructure to the substrate RNAs stoichiometrically. The procedure
stablished in this study satisﬁes both of these critical require-
ents.
The pull-down assay developed in this study has several advan-
ages over the traditional gel-based assay. First, the sample number
ould be easily increased, in contrast to the limited sample number
f the gel-based assay. Ethanol precipitation that is necessary for
el-based assay to eliminate free [-32P]GTP and to reduce volume
f the samples is not necessary for the pull-down assay. Third, the
ull-down assay takes much shorter time of period than gel-based
ssay, because the time for gel electrophoresis is not necessary.
urthermore, the pull-down assay could be automated in future by
sing magnetic beads or multi-titer well plate coated with strep-
oavidin.
In summary, an efﬁcient method to synthesize a Cap 1-RNA sub-
trate and a novel streptavidin–biotin-based pull-down assay that
ay  dramatically increase the efﬁciency of screening for anti-cap-
natching compounds have been established in this study, which
ay  contribute to the development of novel anti-inﬂuenza drugs.
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